Germany's Biotech Bust
Public markets around the world are down; Germany's Neuer Markt is also out. The demise of the exchange once hailed as Europe's most promising will hit more than just Germany's listed stocks. It affects the country's private sector, too, where young companies-and their investors-are frantically seeking ways to weather the storm.
You may also be interested in...
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In January Windhover's editorial staff posted 48 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included our ongoing coverage of Pfizer's acquisition of Wyeth as well as dispatches from the JP Morgan meeting in San Francisco. And we awarded IN VIVO Blog's Deal of the Year. Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month's START-UP.
Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.